

At page 6, line 23 of the specification kindly amend the paragraph to read:

C1 --This invention employs several types of antibodies which specifically bind to given epitopes. More particularly, this invention uses a "first antibody" which specifically binds to the sequence AAEGLDTQRFSG (SEQ ID NO:1), or portion thereof, on CD8 molecules present on the surface of CD8+ cells but does not activate the CD8+ cells once bound thereto. Here, CD8+ cell "activation" means causing CD8+ cells to express  $\gamma$ -interferon (" $\gamma$ -IFN"). This activation can be measured using routine methods such as sandwich ELISA assays, which can be performed using commercially available kits.--

At page 8, line 6 of the specification, kindly amend the paragraph to read:

C2 --The agent that causes dissociation of the immobilized second complex into CD8+ cells and immobilized antibodies can be any agent which successfully competes with the CD8 molecule for specific binding to the first antibody. In the preferred embodiment, this agent is the polypeptide designated CD8-3 having the sequence AAEGLDTQRFSG (SEQ ID NO:1). In one embodiment, the immobilized second antibody comprises an antibody operably affixed to a magnetic bead.--

At page 8, line 25 of the specification, kindly amend the paragraph to read:

C13  
--This invention further provides a polypeptide useful for generating the instant monoclonal antibody that comprises the amino acid sequence AAEGLDLTQRFSG (SEQ ID NO:1). In the preferred embodiment, the polypeptide is the polypeptide designated CD8-3 and having the amino acid sequence AAEGLDLTQRFSG (SEQ ID NO:2). The instant polypeptide can optionally comprises one or more additional amino acid residues at the C-terminal or N-terminal end. In the preferred embodiment, the polypeptide has the sequence NKPKAAEGLDLTQRFSGKRLG (SEQ ID NO:3).--

At page 9, line 5 of the specification, kindly amend the paragraph to read:

C14  
--Finally, this invention provides a kit for use in isolating CD8+ cells which comprises, in separate compartments, (a) an antibody which specifically binds to the sequence AAEGLDLTQRFSG (SEQ ID NO:1) or portion thereof, on CD8 molecules present on the surface of CD8+ cells, but does not activate the CD8+ cells once bound thereto; and (b) an agent which causes the dissociation of a CD8+ cell-antibody complex. In one embodiment, the agent which causes the dissociation of a CD8+ cell-antibody complex comprises the polypeptide having the sequence AAEGLDLTQRFSG (SEQ ID NO:1). In the preferred embodiment, the agent is the polypeptide consisting of the sequence AAEGLDLTQRFSG (SEQ ID NO:1).--

#### REMARKS

In response to the Communication from the Examiner from October 5, 2001 and in accordance with a telephone communication from Examiner Ewoldt who indicated that the amendments to the